Heart Disease
The purpose of this worksheet is to guide initial and recertification assessments. This is a guide only; clinical judgment
is required in each case. This worksheet is completed and signed by the RN and attached to a completed Admission/Recertification Evaluation form. After reviewing the completed paperwork, the Medical Director will sign the Admission/Recert Evaluation form and Recertification form for hospice eligible clients. Client Name: ___________________________ Medical Record Number: _________ Date: _________ The patient must have 1or 2 and 3.
1. Poor response to (or patient’s choice is not to pursue) optimal treatment with diuretics,
vasodilators, and/or angiotensin converting enzyme (ACE) inhibitor
2. The patient has angina pectoris at rest resistant to standard nitrate therapy and is not a
candidate for invasive procedures and/or has declined revascularization procedures
3. New York Heart Association (NYHA)* Class IV symptoms with both of the following:
*See appendix 1 for New York Heart Association (NYHA) Functional Classification
The presence of significant symptoms of recurrent Congestive Heart Failure (CHF) and /or angina at rest
Inability to carry out even minimal physical activity with symptoms of heart failure (dyspnea and/or angina)
Supporting evidence for hospice eligibility: _____Echo demonstrating an ejection fraction of 20% or less _____Treatment resistant symptomatic dysrythmias _____History of unexplained or cardiac related syncope _____CVA secondary to cardiac embolism _____History of cardiac arrest or resuscitation _____ Concomitant HIV disease. _____Wt loss history last 6 months:__________________________________________ _____Systolic b/p less than 90 or progressive postural hypotension _____BMI below 22 kg/22m2 within last 6 months:(dates)_______________________ _____Decreasing arm circumference_________________________________________
Examples of Diuretics, Vasodilators, (ACE) inhibitors:
Diuretics Check all that apply. _____ Furosemide (Lasix) _____ Ethacrynic Acid (Edecrin) _____ Bumetanide (Bumex) _____ Torsemide (Demex) _____ Metolazone (Zarloxlyn, Mykrox – may be combined with above, but not used alone.) Vasodilators Check all that apply. A. Nitrates (e.g., Nitro patch, Isosorbide) plus Hydralazine _____ B. Aprespline Anglotensin Converting Enzyme (ACE) Inhibitor: _____ Benazepril (Lotensin) _____ Lisinopril (Prinvil. Zestril) _____ Captopril (Capoten) _____ Quinapril (Accupril) _____ Enalapril (Vasotec) _____ Ramipril (Altace)
7/15/10 macintosh
hd:users:kjb:library:containers:com.apple.mail:data:library:mail downloads:lcd cardiac.doc
Signs and Symptoms of NYHA Class IV disease: Symptoms
_____ Dyspnea at rest: “short winded,” “can’t breathe.”
_____ Dyspnea on exertion: “Can’ breathe with
_____ Orthopnea: “Can’t breathe lying down.”
_____ Neck veins distended above clavicle.
_____ Paroxysmal nocturnal Dyspnea (PND): “Waking
_____ Rales: Wet crackles in lungs heard on inspiration.
_____ Edema: “Swollen ankles, legs.”
_____ Chest Pain. Co-morbitities/Secondary Conditions that support hospice diagnosis:
Person completing form signature_________________________________________________________Date:____________ RN signature_________________________________________________________Date:_____________
Md. Signature___________________________________________________________Date:_______________
7/15/10 macintosh
hd:users:kjb:library:containers:com.apple.mail:data:library:mail downloads:lcd cardiac.doc
Sehr geehrte Patientin, sehr geehrter Patient, bei Ihnen wurde ein sogenanntes Screening auf M ethicillin R esistente S taphylococcus a ureus (MRSA) durchgeführt. Diese Untersuchung dient dazu, Patienten mit einer MRSA-Besiedelung frühzeitig zu Welche Bedeutung hat MRSA für Sie als Patient? Die natürliche Schutzfunktion der Haut und des Nasen-Rachenraumes wird durch ein Ba
Austin Health – Diabetes Lifestyle Change Program Nicki Gazis – HARP PsychologyAlan McCubbin – HARP DietitianBrett Gordon – Physiotherapy Richard MacIsaac – Endocrinology • Translating evidence from clinical trials into evidence based • Representativeness of trial samples• Generalizability to clinical settings• AH-DLCP modifications• Program outcomes Clini